-
Influenza viruses are enveloped RNA viruses that belong to the family of Orthomyxoviridae and can cause signiflcant morbidity and mortality in humans through epidemics or pandemics, the latter of which has occurred on three occasions in 1918, 1957, and 1968 [12]. The most common infection, seasonal influenza, is usually a mild, self-limited febrile syndrome, but it can be more severe in infants, the elderly, and immunodeficient persons, in whom it can progress to severe viral pneumonitis or be complicated by bacterial superinfection, leading to pneumonia and sepsis. Occasionally, viruses that have spread from wild birds to domestic poultry, such as highly lethal H5N1 avian influenza that first emerged in Hong Kong in 1997 can also infect humans. More recently, genomic segments of a new H1N1 strain were found to be most closely related to swine influenza strains.
Currently available anti-influenza virus drugs target either the viral M2 ion channel (amantadine and rimantadine) or the viral neuraminidase (oseltamivir and zanamivir) [6]. Because Amantadine is not effective against influenza B viruses and can cause adverse effects, it is not recommended [8, 14-16]. A signiflcant increase in amantadine resistance among H3N2 FLUAV circulating in Asia, Australia, North America, and Europe was noticed in recent antiviral surveillance studies [1, 3, 4, 13]. This raises further concerns about the appropriate use of adamantanamines. Moreover, some of the currently circulating human-pathogenic avian H5N1 viruses in South East Asia [2, 5, 11] and other avian FLUAV subtypes [3]are amantadine-resistant.
Due to the high prevalence of amantadine-resistant viruses, neuraminidase inhibitors (NAI) are the only drugs that are currently considered for antiviral therapy of influenza virus infections. However, the 2007-2008 influenza season in the Northern hemi-sphere has shown a marked increase in the number of H1N1 isolates that are resistant to oseltamivir [7, 9].
Another commonly used antiviral agent is virazole, which is used as positive control in our experiment. However, virazole has many side effects such as epileptic seizures, convulsion, somnolence, sinus bradycardia, sinus arrest, urticaria, anaphylactic shock, hemolytic anemia, aplastic anemia, oligoleukocy-themia, impairment of renal and liver functions, systematic bleeding, DIC and angina abdominis. All of these problems restrict its clinic usage. Thus, with the limited range of current treatments and the threat of a new pandemic, influenza drug development remains a high priority.
Folium Isatidis is derived from the dry leaves of the Cruciferae plant -Isatis indigotica Fort. The plant has long been recognized as a herb in Traditional Chinese Medicine, for treatment of influenza, acute infectious hepatitis, dysentery, acute gastroenteritis, acute pneumonia and so on. Modern research has proved that Folium Isatidis has antibacterial, antiviral, antipyretic, anti-inflammatory properties and can promote immunological response. In this study, we extracted a monomer from Folium Isatidis to demonstrate its anti-influenza virus activity in vivo.
HTML
-
From Table 1, the lung index of low, median, high dosage are significantly lower than the virus control groups, F=9248.750, P < 0.01. In addition, the lung index and its inhibitory rate of the FI high-dose has the similar effect with virazole, P=0.086 > 0.05; but is more effective than the antiviral oral liquor, P < 0.01. And there are obvious dose-effect relationship between dosage (25~75 mg/kg/d) and the inhibitory rate of lung index, P < 0.05.r=-0.997, y=2.183-0.011x.
Table 1. The effect of FI against lung index in influenza mice
-
In Table 2, the numbers of "+++~++++" in FI given group are less and the numbers of "±~++" are more than than those in the virus control group. This indicates that the monomers from Folium Isatidis can cure the pneumonia caused by influenza virus somehow.
Table 2. The effect of FI against pathological changes in influenza mice lung
-
From Table 3, the hemagglutination titers in different dosage FI group are much lower than the virus control group, F=1766.000, P < 0.01. Meanwhile, there is a clear dose-effect relationship between the dosage (25-75 mg/kg/d) and inhibitory rate of the lung index, r=0.997, P=0.014 < 0.05. y=0.964-0.005x. And in Fig. 1 the high-dose FI monomer can decrease the hemagglutination titers more effectively than anti-virus oral liquid (P = 0.002 < 0.01), while the same as virazole. (P = 0.086 > 0.05)
Table 3. The effect of FI against influenza virus hemagglutination titer in mice lung
-
After 4 days' infection, the mice began to reduce their activities, lose their weights and appetite, let their hairs erected, chill, crouch and have various degrees of breathing blister sounds. 5 days after infections they began to die, and this phenomenon continued for 2 weeks.
Some mice were able to gradually return to normal conditions, while some can not and begin to die. We count the number of deaths and calculate the survival days in each group for 14 d in Table 4. (If mice are not dead in 14 days, we regard their survival days as 14 days). And there is an obvious relationship between the dose and death rate. Different dosages of FI could significantly reduce the mortality rate (P < 0.01), extend the living time (P < 0.01). In addition, it was proved that the high-dose group differed little from the virazole group(P > 0.05), and is more effective than antiviral oral liquor in its antiviral activity, P < 0.05.
Table 4. The death protection effect of FI to mice infected by influenza virus